4B Technologies Announces Phase 1 Trial Results for 4B03-04, a Potential First-in-Class Non-Opioid Therapy for Chronic Pain

July 14, 2025, 4B Technologies announced topline results from its Phase 1 SAD study of 4B03-04, an investigational humanized monoclonal antibody designed to treat chronic...

The Third First-in-Class Drug for ALS Approved for Clinical Trials | Building a Comprehensive Multi-Mechanism Treatment Matrix

May 19, 2025 – 4B Technologies' independently developed FIC drug candidate 4B02-01 injection has been approved for entering clinical trial by CDE

4B Technologies (Beijing) Co., Ltd was awarded the Certificate of Beijing Foreign-Funded R&D Center issued by the Beijing municipal Science & Technology Commission, Administrative Commission of Zhongguancun Science Park

On December 26, 2024, 4B Technologies (Beijing) Co., Ltd was awarded the Certificate of Beijing Foreign-Funded R&D Center issued by the Beijing municipal Science & Techno...